Dr Bristi Basu

University of Cambridge
Cambridge University Hospitals NHS Foundation Trust

University departments
Department of Oncology
NHS or other affiliations
Honorary Consultant Medical Oncologist

Position: Senior Research Associate
Personal home page: http://www.cambridge-pcc.org/basu.html
Email:   bristi.basu@medschl.cam.ac.uk

PubMed journal articles - click here

Dr Bristi Basu is pleased to consider applications from prospective PhD students.

Research description

I co-lead the Cambridge Experimental Cancer Medicine Centre with Prof Duncan Jodrell and the CRUK Cambridge Centre Pancreatic Cancer Programme with Dr Giulia Biffi. Other roles include Capacity Building leadership team within the Cambridge NIHR Biomedical Research Centre; NCRI Upper GI Hepatobiliary and Pancreatic Cancer subgroups; Cancer Research UK Clinical Research Committee member; Eastern Lead for NIHR CRN Early Phase Cancer Studies Specialty Group. My research focus is in drug development and I translate preclinical findings on lead candidate agents into early phase clinical trials of novel therapeutic drugs as chief investigator, principal investigator and co-investigator in academic-led and industry-sponsored Phase I, II and III clinical trials, including first-in-human and first-in-class studies. My tumour site-specific focus is in hepato-pancreatico-biliary cancers, for which I design novel clinical trials based on preclinical research that has been performed at the Cambridge. I also investigate non-invasive imaging techniques that evaluate pharmacodynamic effects or show potential as early predictors for efficacy of anticancer drugs.

Research Programme or Virtual Institute
Pancreatic Cancer
Strategic Resources
Cambridge Experimental Cancer Medicine Centre (ECMC)
Methods and technologies
Clinical trials
Tumour type interests
Phase I trials
imaging studies
pancreatic cancer
hepatocellular carcinoma
ovarian cancer
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge

Key publications

Martins FC, Couturier DL, de Santiago I, Sauer CM, Vias M, Angelova M, Sanders D, Piskorz A, Hall J, Hosking K, Amirthanayagam A, Cosulich S, Carnevalli L, Davies B, Watkins TBK, Funingana IG, Bolton H, Haldar K, Latimer J, Baldwin P, Crawford R, Eldridge M, Basu B, Jimenez-Linan M, Mcpherson AW, McGranahan N, Litchfield K, Shah SP, McNeish I, Caldas C, Evan G, Swanton C, Brenton JD. Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer. Nat Commun. 2022 Oct 26;13(1):6360. doi: 10.1038/s41467-022-33870-0. PMID: 36289203; PMCID: PMC9606297.

Banerjee S, Michalarea V, Ang JE, Ingles Garces A, Biondo A, Funingana IG, Little M, Ruddle R, Raynaud F, Riisnaes R, Gurel B, Chua S, Tunariu N, Porter JC, Prout T, Parmar M, Zachariou A, Turner A, Jenkins B, McIntosh S, Ainscow E, Minchom A, Lopez J, de Bono J, Jones R, Hall E, Cook N, Basu B, Banerji U. A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer. Clin Cancer Res. 2022 Aug 19:CCR-22-1268. doi: 10.1158/1078-0432.CCR-22-1268. Epub ahead of print. PMID: 35984704.

Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner AJ, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez JS, Minchom A, de Bono JS, Banerji U. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncol. 2020 Nov;21(11):1478-1488. doi: 10.1016/S1470-2045(20)30464-2. Epub 2020 Oct 28. Erratum in: Lancet Oncol. 2021 Feb;22(2):e42. PMID: 33128873.

Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci U S A. 2020 Oct 30:202013644. doi: 10.1073/pnas.2013644117. Epub ahead of print. PMID: 33127761.

Hemant M Kocher, Bristi Basu, Fieke EM Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M deSouza, Katja N De Paepe, Michelle R Goulart, Christine Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast, David J Propper. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nature Comm 2020 Sep 24 10.1038/s41467-020-18636-w

Yap TA, Kristeleit R, Michalarea V, et al. Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. Cancer Discov. 2020;CD-20-0163. doi:10.1158/2159-8290.CD-20-0163

Sarker D, Plummer R, Meyer T, et al. MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial. Clin Cancer Res. 2020;clincanres.0414.2020. doi:10.1158/1078-0432.CCR-20-0414

Corrie PG, Qian W, Basu B, Valle JW, Falk S, Lwuji C, Wasan H, Palmer D, Scott-Brown M, Wadsley J, Arif S, Bridgewater J, Propper D, Gillmore R, Gopinathan A, Skells R, Bundi P, Brais R, Dalchau K, Bax L, Chhabra A, Machin A, Dayim A, McAdam K, Cummins S, Wall L, Ellis R, Anthoney A, Evans J, Ma YT, Isherwood C, Neesse A, Tuveson D, Jodrell DI. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Br J Cancer. 2020 Apr 30. doi: 10.1038/s41416-020-0846-2. PubMed PMID: 32350413

Gallagher FA, Woitek R, McLean MA, Gill AB, Manzano Garcia R, Provenzano E, Riemer F, Kaggie J, Chhabra A, Ursprung S, Grist JT, Daniels CJ, Zaccagna F, Laurent MC, Locke M, Hilborne S, Frary A, Torheim T, Boursnell C, Schiller A,Patterson I, Slough R, Carmo B, Kane J, Biggs H, Harrison E, Deen SS, Patterson A, Lanz T, Kingsbury Z, Ross M, Basu B, Baird R, Lomas DJ, Sala E, Wason J, RuedaOM, Chin SF, Wilkinson IB, Graves MJ, Abraham JE, Gilbert FJ, Caldas C, Brindle KM. Imaging breast cancer using hyperpolarized carbon-13 MRI. Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):2092-2098. doi: 10.1073/pnas.1913841117. Epub 2020 Jan 21. PubMed PMID: 31964840; PubMed Central PMCID: PMC6995024

Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res.2020 Mar 1;26(5):1009-1016. doi: 10.1158/1078-0432.CCR-19-1638. Epub 2019 Dec 12. PubMed PMID: 31831561; PubMed Central PMCID: PMC7056559

*Basu B, *Krebs MG, *Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, de Oliveira FM, Carreira S, Swales K, Ruddle R, Raynaud FI, Purchase B, Dawes JC, Parmar M, Turner AJ, Tunariu N, Banerjee S, de Bono JS, Banerji U. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann Oncol. 2018 Sep 1;29(9):1918-1925. doi: 10.1093/annonc/mdy245 * joint 1st authors

N Cook, B Basu, D-M Smith, A Gopinathan, J Evans, W Steward, D Palmer, D Propper, B Venugopal, M Hategan, A Anthoney, L Hampson, M Nebozhyn, D Tuveson, H Farmer-Hall, H Turner, R McLeod, S Halford, D Jodrell “A Phase I trial of the ɣ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma” British Journal of Cancer 2018 Feb 13. doi: 10.1038/bjc.2017.495

FM Walter, K Mills, S Mendonca, G Abel, B Basu, N Carroll, S Ballard, J Lancaster, W Hamilton, GP Rubin, JD Emery. “Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer: a prospective cohort study” The Lancet Gastroenterology & Hepatology 2016 1: 298–306 http://dx.doi.org/10.1016/S2468-1253(16)30079-6

B Basu*, E Dean*, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, G Bigley, C Womack, E A Harrington, S Green, E Oelmann, J S de Bono, M Ranson, U Banerji. “First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014” Clinical Cancer Research *Joint first authors 2015 Aug 1;21(15):3412-9

B Basu, P Correa-Sampaio, H Mohammed, M Fogarasi, W English, N Watkins, P Corrie, W Ouwehand, G Murphy. “Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain” International Journal of Biochemistry and Cell Biology 2012 Feb; 44(2): 393-403.